The Effect of Semaglutide on Bone Health

Semaglutide has effects that include lowering blood sugar, reducing weight, and improving cardiovascular and renal outcomes, and it is now widely used in clinical practice. Given that weight loss is associated with bone loss, its effect on bone health has recently raised concerns. Therefore, the goal of this clinical trial is to learn the effect of semaglutide on bone mineral density and fractures in patients with type 2 diabetes. The investigators will compare semaglutide combined with metformin to metformin alone to see if semaglutide treatment has effects on bone mineral density and bone turnover markers in patients with type 2 diabetes after 12 months. The intervention group will receive semaglutide combined with metformin for 12 months, while the control group will receive metformin alone for the same duration. After 12 months of treatment, the investigators will compare the bone mineral density, fracture incidence, and levels of bone turnover markers between the two groups.

NCT Number	NCT07165158
Lead Sponsor	The First Affiliated Hospital of Xiamen University Collaborators: Peking University First Hospital, Shanghai Punan Hospital of Pudong New District, Shanghai 6th People's Hospital, Jinzhou Medical University
Conditions	Osteoporosis, Osteoporosis Fracture, T2DM
Enrollment	150 participants
Start Date	2025-09-15
Primary Completion	2026-12-31 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-09-17